The design, synthesis and biological evaluation of a novel series of oxazinyl isoflavonoids is described. Several analogs were shown to exhibit growth inhibitory effects against SKOV-3, DU-145 and HL-60 human colon cancer cell lines with IC 50 values in the micromolar range. The cellular potency of compounds 7e and 12h were found to have greater in vitro inhibitory activities than phenoxodiol, the parental compound currently in late-stage clinical trials for the treatment of cancer. The results shown are suitable for further lead optimization.Key words anti-tumor activity; oxazinyl isoflavonoid compound; synthesis With the changes in the current living environment, cancer has become the second leading cause of death in developed countries. Over 1 million cases of cancer occur in the United States annually, and cancer-related deaths are estimated to reach 12 million worldwide by the year 2015.